Reuters logo
BRIEF-Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy
August 28, 2017 / 12:51 PM / 3 months ago

BRIEF-Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy

Aug 28 (Reuters) - Anthera Pharmaceuticals Inc:

* Anthera announces top line final data from the extension period of the phase 2 bright-sc study of blisibimod in patients with IgA nephropathy

* Anthera Pharma- blisibimod was well tolerated with substantially more patients on placebo arm discontinuing from study than those receiving blisibimod Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below